



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Levitt et al.

Serial No.: 09/939,209

Filed: August 24, 2001

Art Unit: 1636

Examiner: C. Qian

Atty. Docket No.: 00-539-US

RECEIVED

SEP 26 2003

TECH CENTER 1600/2900

**METHODS AND SYSTEMS FOR
FACILITATING THE DIAGNOSIS
AND TREATMENT OF
SCHIZOPHRENIA**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being

MAILED

FACSIMILE

deposited with the United States Postal Service on September 19, 2003, with sufficient postage as first-class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

transmitted by facsimile on [date] to the U.S. Patent and Trademark Office.

Type Signature Name

(Signature of person mailing paper or fee)

Lou B. Amoroso

Lou B. Amoroso

(Signature of person mailing paper or fee)

1. Enclosed is PTO Form 1449 (and a duplicate thereof).
2. Items listed on the enclosed Form PTO-1449 are not in the English language.
 - For each of the following items, an English-language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
 - For each of the following items, a concise explanation of that item is incorporated in the specification of the above-identified application;
 - For each of the following items, a corresponding U.S. or other English-language patent is enclosed. Please consider the U.S. or other English-language patents in accordance with the procedure set forth in MPEP § 609:

3. **Submission in Accordance with 37 CFR § 1.98(d).**

Any copy of the items listed on the enclosed Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in Application Serial No. [Ser. No.], filed [Date], of which the present application relies upon for an earlier filing date under 35 U.S.C. 120.

4. **Submission in Accordance with 37 CFR § 1.97(b).**

This Information Disclosure Statement is being filed

- With the application;
- Within three months of the filing date of a national application;
- Within three months of the date of entry of the national stage in an international application; or
- Before the mailing date of a first Office Action on the merits.

and NO FEE is due for consideration of this Information Disclosure Statement.

5. **Submission in Accordance with 37 CFR 1.97(c).**

This Information Disclosure Statement is being filed before the first mailing date of either

- A final action under § 1.113; or
 - A notice of allowance under § 1.311.
- A fee is due for consideration of this Information Disclosure Statement and the fee is paid below; or

- This Information Disclosure Statement is accompanied by one of the certifications pursuant to 37 CFR § 1.97(e), and NO FEE is due for consideration of this Information Disclosure Statement.

6. **Submission in Accordance with 37 CFR 1.97(d).**

This Information Disclosure Statement is being filed after the mailing date of either

- A final action under § 1.113; or
 A notice of allowance under § 1.311.

whichever comes first, but before payment of the issue fee, and is accompanied by

- a. One of the certifications pursuant to 37 CFR § 1.97(e), which is set forth below;
- b. The attached petition requesting consideration of this Information Disclosure Statement; and
- c. The petition fee under 37 CFR § 1.17(i)(1), which is paid below.

7. **Certification Pursuant to 37 CFR 1.97(e).**

- The undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application not more than three months prior to the filing of this Information Disclosure Statement; or
- The undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

8. **Fee Payment Being Made.**

- Enclosed
- \$180.00 fee for submission under 37 CFR § 1.97(c).
- \$180.00 fee for submission under 37 CFR § 1.97(d).
- A check in the amount of \$[Amount] to cover the fee payment is enclosed.
- Charge the fee to Deposit Account No. 18-0582. A duplicate copy of this communication is attached.
- The Director is hereby authorized to charge payment of any additional fees associated with this Information Disclosure Statement or credit any overpayment

Serial No.: 09/939,209
Docket No.: 00-539-US

to Deposit Account No. 18-0582. A duplicate copy of this communication is enclosed.

Respectfully submitted,

Dated: September 19, 2003

By 
James G. Dilmore
Reg. No. 51,618

Frederick H. Colen
Reg. No. 28,061

REED SMITH LLP
P.O. Box 488
Pittsburgh, PA 15230-0488
(412) 288-3813

Agent for Applicants

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 00-539-US	SER. NO. 09/939,209 RECEIVED
OPIA SEP 22 2003 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))		APPLICANT LEVITT et al.	SEP 26 2003
		FILING DATE August 24, 2001	GROUP TECH CENTER 1600/2800 1636

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/Subclass	Filing Date

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/Subclass	Translation Yes/No

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
_____	1	LIBIN, B. JIA et al.: "Human bone marrow stromal cells Homo sapiens cDNA clone" retrieved from EMBL, accession no. AI754847 Database accession no. AI754847; DATABASE EBI 'Online! EMBL; 29 June 1999
_____	2	STRAUSBERG, R.: "H. sapiens cDNA clone" retrieved from EMBL, accession no. AA595701 Database accession no. AA595701; DATABASE EBI 'Online! EMBL; 24 September 1997
_____	3	ABOLA, A. P. et al.: "Homo sapiens chromosome 1 clone RP11-288018" retrieved from EMBL, accession no. AC031977 Database accession no. AC031977; DATABASE EBI 'Online! EMBL; 5 April 2000
_____	4	DRUEY, KIRK M et al.: "Inhibition of regulator of G protein signaling function by two mutant RGS4 proteins." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 24, 25 November 1997 (1997-11-25), pages 12851-12856, Nov. 25, 1997
_____	5	SRINIVASA, S P et al.: "Plasma membrane localization is required for RGS4 function in <i>Saccharomyces cerevisiae</i> ." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 12 May 1998, vol. 95, no. 10, 12 May 1998 (1998-05-12), pages 5584-5589

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) U.S. PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.


00-539-US

SER. NO.

09/939,209

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(37 CFR 1.98(b))



APPLICANT

LEVITT et al.

FILING DATE

August 24, 2001

GROUP

163 TECH CENTER 15002900

RECEIVED

SEP 26 2003

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
_____	6	PULVER, A E: "Search for Schizophrenia susceptibility genes" BIOLOGICAL PSYCHIATRY, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 47, 1 February 2000 (2000-02-01), pages 221-230
_____	7	DE VRIES, L et al.: "The regulator of G protein signaling family." ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, UNITED STATES 2000, vol. 40, 2000, pages 235-271
_____	8	HEPLER, JR: "Emerging roles for RGS proteins in cell signalling" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 20, no. 9, 1 September 1999 (1999-09-01), pages 376-382
_____	9	NI YAN G et al.: "Region-specific regulation of RGS4 (regulator of G-protein-signaling protein type 4) in brain by stress and glucocorticoids: In vivo and in vitro studies." JOURNAL OF NEUROSCIENCE, vol. 19, no. 10, 15 May 1999 (1999-05-15), pages 3674-3680

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.